Additionally, it explores targeted therapies, including kinase inhibitors and Proteolysis Targeting Chimeras (PROTACs), and discusses the potential of using LRRK2 as a biomarker for PD diagnosis and bioassay development. Here, LRRK2 is linked to Parkinson disease.